In order to solve the problem of raw materials, the pharmaceutical company is "married" with overseas companies

[pharmaceutical network industry trends] the shortage of APIs has been plaguing the pharmaceutical industry, which has brought hidden dangers to the normal supply of patients' medication Since this year, there has been a shortage and shortage of nitroglycerin tablets, a common drug for coronary heart disease and angina pectoris, and the price has been soaring like a rocket According to media reports from all over the world: Weifang citizens went to three pharmacies to buy nitroglycerin tablets, and the original price was only a few yuan, but now it has risen to more than 40 yuan or even 50 yuan / box; Xiamen coronary heart disease patients went to many pharmacies, but they also did not buy the same medicine, which was later bought, not only the number of tablets decreased, but also the price increased four or five times; citizens in Harbin, Nanjing, Chengdu and other places In fact, as early as February 22 this year, a local government issued the notice on directly listing nitroglycerin tablets and other drugs in short supply, listing nitroglycerin tablets as short drugs, which can be directly purchased online Behind the "drug shortage" and double price of nitroglycerin tablets, the industry believes that on the one hand, the raw materials of nitroglycerin tablets are in serious shortage, and now the cost of raw materials and drug packaging is rising, so the drug price is naturally rising; on the other hand, many raw materials such as nitroglycerin tablets are "monopolized" and the cost is rising, which directly makes the drug price rise At present, there are 13 pharmaceutical factories approved by the State Drug Administration to produce nitroglycerin tablets, but many pharmaceutical companies have not produced or sold relevant products although they hold approval numbers Among them, Beijing Yimin pharmaceutical industry occupies nearly 80% market share of nitroglycerin tablets Environmental protection and safety are the weak points of API With the increase of environmental protection in recent years, API enterprises need to invest a lot of funds to deal with environmental protection, or move, transform, some small and medium-sized enterprises are facing the situation of shutdown, bankruptcy, which has a certain impact on the supply of API For example, Yimin pharmaceutical industry has moved before, or caused insufficient production capacity In view of the shortage of APIs, downstream pharmaceutical companies are also looking for stable production methods Some enterprises choose to establish their own API production bases to achieve "self-sufficiency" There are also API companies that choose to sign framework agreements with overseas companies to solve the problem of controlled raw materials Recently, Zhendong pharmaceutical announced that Zhendong ante, a subsidiary of the company, recently signed a framework agreement with dipharma Fracis S.r.l to solve the problem of controlled raw materials of nitroglycerin tablets The announcement shows that the above agreement is applicable to any written purchase order submitted by Zhendong ante to dipharma Fracis S.r.l for the supply of goods or products (purchase order and goods) The agreement shall remain in full force and effect with respect to any purchase order until either party provides written notice of termination to the other party for not less than six months, or until its termination date Zhendong pharmaceutical said the signing of the agreement will solve the dilemma of the raw material control of Zhendong special product Nitroglycerin Tablets, which has a positive impact on the company's performance According to the announcement, dipharma Francis S.r.l was founded in February 1990 with a registered capital of 8.4 million euros NACE code is the primary form of manufacturing basic chemicals, plastics and synthetic rubber The data shows that Zhendong pharmaceutical is a large-scale comprehensive pharmaceutical enterprise in China, which mainly produces eight drug series, including vitamin nutrition, anti-tumor, cardio cerebrovascular, anti infection, digestive system, respiratory system, antipyretic and analgesic, nervous system, etc